title: Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma (CACG).
  
  
  METHODS
  Pertinent publications were identified through systematic searches of PubMed, EMBASE, the Cochrane Controlled Trials Register and the Chinese Biomedicine Database. Randomized controlled trials comparing latanoprost with timolol in patients with chronic angle-closure glaucoma (CACG) who had inadequate intraocular pressure (IOP) control after peripheral iridotomy (PI) were selected. The main efficacy measures were the weighted mean difference (WMD) in the reduction from baseline to end of treatment in IOP at peak, trough, and diurnal curve. The main tolerability measures were the odds ratio (OR) for the individual adverse events. The pooled estimates and 95% confidence intervals (CIs) were carried out in RevMan version 5.2 software.
  
  
  RESULTS
  Five published randomized controlled trials involving 528 patients were included in the present meta-analysis. The IOP reduction (IOPR) was significantly greater in the latanoprost group than in the timolol group at diurnal curve (WMD: 2.22 mmHg [95% CI, 1.65 to 2.79], P < 0.00001), peak (WMD: 2.44 mmHg [0.85 to 4.03], P = 0.003) and trough (WMD: 2.67 mmHg [1.93 to 3.41], P < 0.00001). Timolol caused conjunctival hyperemia in less patients than latanoprost (pooled OR: 2.74 [95% CI, 1.33 to 5.61], P = 0.006).
  
  
  CONCLUSIONS
  Latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. Latanoprost caused conjunctival hyperemia in more patients than timolol. Further clinical trials are needed because of short duration of included studies.
authors.affiliation: Shanghai Changzheng Hospital, Second Military Medical University , Shanghai , China.
authors.forename: Heng
authors.initials: H
authors.lastname: Lou
authors.forename: Ying
authors.initials: Y
authors.lastname: Zong
authors.forename: Yi-Rui
authors.initials: YR
authors.lastname: Ge
authors.forename: Jin-Wei
authors.initials: JW
authors.lastname: Cheng
authors.forename: Rui-Li
authors.initials: RL
authors.lastname: Wei
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013999:Timolol / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol
keywords: Intraocular pressure; Latanoprost; Meta-analysis; Timolol